About C-C chemokine receptor type 1
C-C chemokine receptor type 1 (CCR1) is a protein
from Homo sapiens identified by UniProt accession
P32246, 355 residues long.
MolForge cross-references it against 0 known binders and
522 disease associations.
Target properties
| Protein name | C-C chemokine receptor type 1 |
| UniProt accession | P32246 |
| Gene | CCR1 |
| Organism | Homo sapiens |
| Length | 355 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (522)
Diseases linked to this target (Open Targets).
- basophil count · score 0.27
- glioblastoma multiforme · score 0.26
- celiac disease · score 0.23
- mean corpuscular hemoglobin · score 0.22
- basophil percentage of leukocytes · score 0.18
- mean corpuscular volume · score 0.18
- breast adenocarcinoma · score 0.17
- head and neck squamous cell carcinoma · score 0.17
- CCL4 measurement · score 0.16
- Behcet's syndrome · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P32246-F1 | alphafold | PREDICTED | 83.18 | — |
Amino-acid sequence (355 residues)
METPNTTEDY DTTTEFDYGD ATPCQKVNER AFGAQLLPPL YSLVFVIGLV GNILVVLVLV QYKRLKNMTS IYLLNLAISD LLFLFTLPFW IDYKLKDDWV FGDAMCKILS GFYYTGLYSE IFFIILLTID RYLAIVHAVF ALRARTVTFG VITSIIIWAL AILASMPGLY FSKTQWEFTH HTCSLHFPHE SLREWKLFQA LKLNLFGLVL PLLVMIICYT GIIKILLRRP NEKKSKAVRL IFVIMIIFFL FWTPYNLTIL ISVFQDFLFT HECEQSRHLD LAVQVTEVIA YTHCCVNPVI YAFVGERFRK YLRQLFHRRV AVHLVKWLPF LSVDRLERVS STSPSTGEHE LSAGF
Explore C-C chemokine receptor type 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets